Myriad Genetics to acquire diagnostic company Crescendo

06-02-2014

Myriad Genetics has entered into a definitive agreement to acquire inflammatory and autoimmune diagnostics company Crescendo Bioscience for $270 million.


Myriad, Crescendo, diagnostics, rheumatoid arthritis, mergers and acquisitions

LSIPR